- Title: U.S. authorizes Moderna, Pfizer/BioNTech vaccine boosters retooled for Omicron
- Date: 31st August 2022
- Summary: NEW YORK, NEW YORK, UNITED STATES (FILE - NOVEMBER 9, 2020) (REUTERS) VARIOUS OF PFIZER HEADQUARTERS WASHINGTON, D.C., UNITED STATES (FILE - MAY 6, 2021) (REUTERS) WIDE SHOT OF PEOPLE SEATED AT VACCINE SITE VARIOUS OF MEN GETTING COVID-19 VACCINE SHOT
- Embargoed: 14th September 2022 16:06
- Keywords: COVID-19 FDA Moderna Pfizer boosters coronavirus
- Location: NEW HYDE PARK + NEW YORK, NEW YORK / LOS ANGELES, CALIFORNIA / SEATTLE, WASHINGTON / KALAMAZOO, MICHIGAN / WASHINGTON, D.C., UNITED STATES
- City: NEW HYDE PARK + NEW YORK, NEW YORK / LOS ANGELES, CALIFORNIA / SEATTLE, WASHINGTON / KALAMAZOO, MICHIGAN / WASHINGTON, D.C., UNITED STATES
- Country: USA
- Topics: Health/Medicine,United States
- Reuters ID: LVA003186131082022RP1
- Aspect Ratio: 16:9
- Story Text: The U.S. Food and Drug Administration on Wednesday (August 31) authorized the retooled COVID-19 booster shots of both Moderna and Pfizer/BioNTech that target the currently dominant BA.4/BA.5 Omicron subvariants of the coronavirus.
Both vaccines include the original version of the virus targeted by all the previous COVID shots as the country prepares for another vaccination campaign in the fall season.
The FDA authorized Moderna's vaccine for those aged 18 and above and Pfizer's for those aged 12 and above to be given at least two months after the primary vaccination series or the most recent booster shot.
The U.S. government has secured 105 million doses of Pfizer's updated shots and 66 million doses of Moderna's bivalent vaccine to stave off the worst effects of a likely surge in infections as schools reconvene and people spend more time indoors as the weather grows colder.
Pfizer said it has some doses ready to ship immediately and can deliver up to 15 million doses by Sept 9.
The FDA in June asked vaccine makers to tailor shots to the two subvariants responsible for the most recent surge in infections worldwide. The BA.5 subvariant accounts for more than 88% of U.S. infections.
The vaccine makers have not completed testing of the updated BA.4/BA.5-based boosters in humans. The FDA is basing its decision on safety and effectiveness data from the original shots as well as from clinical trials conducted on bivalent boosters using the BA.1 Omicron subvariant.
The U.S. Centers for Disease Control and Prevention's vaccine advisory panel is scheduled to meet on Thursday (September 1) to make recommendations for use of the redesigned shots that Director Rochelle Walensky will take into consideration before making a final decision.
(Production: Vanessa Johnston) - Copyright Holder: FILE REUTERS (CAN SELL)
- Copyright Notice: (c) Copyright Thomson Reuters 2022. Open For Restrictions - http://about.reuters.com/fulllegal.asp
- Usage Terms/Restrictions: None